https://www.selleckchem.com/pr....oducts/gsk1016790a.h
Our prognostic model using these parameters could classify patients into good (n = 32) and poor (n = 24) prognostic groups. The median PFS and OS were longer in good than in poor prognostic group, but the difference in PFS was very small (PFS 2.1 vs. 1.4 months, P = 0.01. OS 6.8 vs. 2.4 months, P 0.01). Interstitial pneumonia occurred in one patient (1.8%). Benefits of erlotinib plus gemcitabine as late-line chemotherapy were limited, particularly with respect to PFS. Development of more effective third-line treatment options i